In our colorectal cancer (CRC) explant model, we also found that a PIK3CA mutation was associated with increased sensitivity to saracatinib and that Src inhibition resulted in a decrease in the activation of the Src and Akt pathways [38]. The gene discussed is PIK3CA; the disease is colorectal carcinoma.